Sichenzia Ross Ference Kesner LLP Represents Immuron Limited on $6.1M IPO and NASDAQ listing
Press Release — New York, NY — June 14, 2017 — Sichenzia Ross Ference Kesner LLP (“SRFK”) announced today the Firm has represented Immuron Limited (NASDAQ: IMRN) (ASX : IMC), a clinical-stage biopharmaceutical company focused on NASH and OTC products, on the company’s U.S. underwritten public offering of American Depository Shares (ADSs) and warrants to purchase the company’s ADSs at a combined offering price of $10.00.
Each ADS represents 40 shares of the company’s ordinary shares. Immuron raised approximately $6,100,000 in gross proceeds, which will be used to advance their products, platform technologies, working capital, and general corporate purposes.
SRFK successfully advised the process by which Immuron listed its ADSs and warrants on NASDAQ under the symbols “NASDAQ:IMRN and IMRNW” respectively, which began trading on June 9, 2017.
The Sichenzia Ross Ference Kesner LLP team was led by Partners Gregory Sichenzia, Darrin M. Ocasio, and David Manno.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $2.3 Million Public Offering of Common Stock of Sigma Labs, Inc. - August 3, 2019
- Sichenzia Ross Ference LLP Ranked as a Top Issuer Counsel for 2019 Q2 - July 24, 2019
- Sichenzia Ross Ference LLP Represents ThinkEquity in $1.35 Million Underwritten Public Offering of ADSs of Immuron Limited - July 23, 2019